spacer
home > epc > spring 2009 > ediary time
PUBLICATIONS
European Pharmaceutical Contractor

eDiary Time

Back in the days of pen and paper clinical trials monitoring, something familiar but disconcerting caught my attention as I got out of the car. There in the next car sat a patient busy filling in his diary card with peak expiratory flow (PEF) readings and symptoms for the past month. Mentioning this to the investigating consultant, he called the patient in, commended him for having a complete diary, and then as he rubbed his finger over it, said, “oh dear the ink is still wet!” Having observed this, I concluded that there had to be a better way of recording diary data. The answer came in the early 1990s with the development of e-spirometric diaries. Chowienczyk et al compared paper versus electronic recording of spirometry data, demonstrating that 33 per cent of completed entries were either invented, mistimed or misread, and were often retrospectively entered (1). Since then, other studies have confirmed that paper diaries often contain invented data (2,3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Initially qualifying as an entomologist, Aleck Harrison swiftly moved from ‘bugs to drugs’ and spent 34 years with Boehringer Ingelheim Ltd. Evolving from CRA to managing international respiratory studies, he advised a number of companies on spirometric diary development. Having semiretired, he started the consultancy of AJH Partners (Contract Research and Consultancy). Amongst his recent activities, he has supported respiratory companies, including Vitalograph Ltd, with the introduction and development of their centralised spirometry system.

spacer
Aleck Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement